Showing results (41-50 of 224) with videos related to
Sort By:
Pageof 23
Stroke|October 26, 2018
Decline in the Severity of Carotid Atherosclerosis and Associated Risk Factors From 2002 to 2014Daniel G Hackam, J David SpenceThe Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|September 21, 2004
Progress in clinical neurosciences: pharmacotherapies for the secondary prevention of strokeDaniel G Hackam, Moira K KapralStroke|April 24, 2010
Treating arteries instead of risk factors: a paradigm change in management of atherosclerosisJ David Spence, Daniel G HackamThrombosis and Haemostasis|June 8, 2013
Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromesVictor L Serebruany, James J DiNicolantonioOpen Heart|April 21, 2015
Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand?Flávio Danni Fuchs, James J DiNicolantonioMedical Hypotheses|June 11, 2015
Is fructose malabsorption a cause of irritable bowel syndrome?James J DiNicolantonio, Sean C LucanMedical Hypotheses|July 11, 2020
Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamoleJames J DiNicolantonio, Jorge Barroso-ArandaTherapeutic Advances in Chronic Disease|July 3, 2015
P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal useNicholas B Norgard, James J DiNicolantonioMedical Hypotheses|May 11, 2020
Targeting Casein kinase 2 with quercetin or enzymatically modified isoquercitrin as a strategy for boosting the type 1 interferon response to viruses and promoting cardiovascular healthJames J DiNicolantonio, Mark F McCartyHealthcare (Basel, Switzerland)|January 21, 2022
Maintaining Effective Beta Cell Function in the Face of Metabolic Syndrome-Associated Glucolipotoxicity-Nutraceutical OptionsMark F McCarty, James J DiNicolantonioPageof 23